This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.
from News Medical Medical Research News Feed https://ift.tt/LKC8tNO

0 Comments